Citicoline (CDP-choline) decisions belong in a visit, not in a checkout. These questions are a list, not advice.
Bring one situation, not a stack. Ask which outcome you care about, and whether any citicoline trial actually enrolled people in that situation. Ask who paid for that trial. Ask what the largest trial found when a large trial exists. For acute stroke, the largest trial found no improvement over placebo. For traumatic brain injury, COBRIT did not improve outcomes over placebo.
Ask about your current medicines, especially levodopa. Ask whether pregnancy, breastfeeding, or a planned procedure changes the answer. Ask what would count as a reason to stop.
Write the answers down. This page cannot hear them.
Most supplement pages end with a verdict: take it or skip it. This page does something different, and the reason is the evidence itself. Citicoline (CDP-choline) has been studied in stroke, brain injury, age-related cognitive decline, glaucoma, and attention, and the results point in different directions depending on the condition, the trial size, and who paid for the study. A single verdict would hide that. A good conversation with your doctor will not.
The goal of the visit is not to get permission to buy a bottle. It is to find out whether your situation matches any situation that has actually been studied, and if so, what the best and largest studies found. That is a harder question than "is citicoline good?" and it is the one worth asking.
The single most useful question you can bring is: "Has citicoline been studied in people like me?"
This matters because the evidence is not interchangeable across conditions. A trial in people with acute stroke tells you nothing reliable about a healthy adult who wants better focus at work. A trial in older adults with chronic cerebrovascular disease tells you nothing about a teenager with attention problems. When you read that "citicoline was studied for cognition," that phrase covers several very different groups with very different results.
So start by naming your situation in plain words. Then ask whether a trial enrolled that group. If the answer is no, as it is for ADHD, where there are no adequate trials, then the honest conclusion is that there is no good evidence for that use, and any claim you have seen elsewhere is running ahead of the science. The evidence hub is organized condition by condition for exactly this reason.
When a topic has many studies, the biggest and best-run ones deserve the most weight. For citicoline, that principle changes the picture in two important areas.
For acute stroke, earlier meta-analyses suggested benefit. But the largest trial, ICTUS, published in The Lancet in 2012 with about 2,300 participants, found no improvement in 90-day recovery compared with placebo. That is the trial your doctor should weigh most heavily, and it is a negative result. The earlier positive signals were not confirmed when the question was tested at scale.
For traumatic brain injury, the COBRIT trial, published in JAMA in 2012, found that citicoline did not improve functional or cognitive outcomes versus placebo. Again, the rigorous answer is a negative one.
Neither result means citicoline is dangerous or useless in every context. They mean that for two of the most serious conditions it has been tested in, the strongest evidence shows no benefit over placebo. If your situation is a recent stroke or a brain injury, that is the starting point for the conversation, not a footnote.
And a separate point that cannot wait for any appointment: sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately. Supplements are never the response to stroke symptoms.
Some citicoline findings are more encouraging, and they deserve a place in the conversation too, with their limits attached.
For chronic cerebrovascular cognitive decline, a Cochrane review by Fioravanti and Yanagi found modest short-term benefit on memory and behaviour. But the underlying trials were short and of low quality. "Modest, short-term, low-quality" is a real finding, and it is also a weak foundation for a long-term decision. Worth asking about; not worth overstating.
For mild vascular cognitive impairment, the IDEALE study was observational: people taking citicoline had stable scores while an untreated group declined. Observational designs cannot prove cause. People who choose to take a supplement often differ from people who do not in ways that affect their health anyway. Ask your doctor how much weight a study like that can carry.
For glaucoma, small trials from the Parisi and Rossetti groups showed changes in electrophysiological measures. Whether that translates into slowing actual vision loss is not established. If you have glaucoma, this is a question for your ophthalmologist alongside your prescribed treatment, never instead of it.
For attention in healthy people, two small trials by McGlade and colleagues found better attention-test scores in women at 250 and 500 mg, and gains in attention and psychomotor speed in adolescent males. Both were funded by Cognizin, the company that sells the branded ingredient. Industry funding does not make results false, but it is a fact you and your doctor should know when judging how much confidence to place in them.
Interactions are the part of the conversation most likely to change the answer. The clearest one for citicoline involves levodopa: citicoline may enhance levodopa's effects. If you have Parkinson's disease and take levodopa, your neurologist needs to be part of this decision before you start anything, not after.
Beyond that specific interaction, bring a full list of what you take, including other supplements. Trials generally found citicoline well tolerated at 250 to 2,000 mg per day, with mild side effects such as stomach upset, headache, and insomnia. "Well tolerated in trials" still leaves open how it fits with your particular combination of medicines and conditions. The side effects page and the page on doses used in studies give you the background; your doctor supplies the context.
Two more groups should raise this explicitly. Pregnancy and breastfeeding data are lacking, which means the honest answer for those situations is that safety is unknown, not that it is fine. And if you have a procedure planned, ask whether the supplement should be stopped beforehand, a question worth asking about anything you take regularly.
Starting a supplement is easy. Knowing when to stop is the part people skip. Before you leave the visit, agree on three things.
First, the outcome. What, specifically, are you hoping changes, and over what time frame? If the answer is vague, the trial evidence will not map onto it, and you will have no way to judge whether anything happened.
Second, the stop conditions. Which side effects would mean stopping right away? If nothing has changed after a reasonable period, is the plan to stop or to keep going indefinitely? An open-ended trial of one is how people end up taking things for years with no benefit.
Third, the follow-up. When will you revisit the question, and with what information? Writing the answers down during the visit matters, because memory of a conversation fades faster than the supply in the bottle.
You do not need to prepare much, but a few things make the visit sharper.
This site can tell you what the trials found, how big they were, who funded them, and where the evidence is thin. It cannot weigh that against your history, your medicines, and your risks. It also cannot respond to symptoms, if you think something is wrong right now, the move is a phone call to a clinician or to 911, not a contact form.
If you want the background first, read what citicoline is, the safety overview, and the condition pages such as citicoline and memory, citicoline and ADHD, and citicoline and glaucoma. Then take the questions. The list is short on purpose: the visit is the long version.
No. It is a list so the visit covers the evidence gap, the dose, and your medicines.
Sudden facial droop, arm weakness, or speech difficulty is an emergency. Call 911. Do not save that question for a supplement visit.
No. The contact form is not a medical consultation.
The evidence hub names the trials to look up, without invented PMID numbers.
Yes, if you already have one. The milligrams on the label are the fact to compare with study doses.
No. The grade of the evidence is here. The decision is theirs, with you.
This site reports what studies found. It does not choose a dose for you.